Results 21 to 30 of about 11,284,409 (311)
Simultaneous Determination of Levodopa and Carbidopa from Fava Bean, Green Peas and Green Beans by High Performance Liquid Gas Chromatography [PDF]
Journal of Clinical and Diagnostic Research, 2013 Introduction: According to many studies, sprouted fava beans are a rich source of levo-dihydroxy phenylalanine (L-dopa) the precursor of dopamine, and they are now being investigated for use in the management of Parkinson’s disease.
Mohseni Mehran S.M., Golshani B.
doaj +1 more source
Frontiers in Aging Neuroscience, 2021 BackgroundIt remains unclear why patients with young-onset Parkinson’s disease more often develop levo-dihydroxyphenylalanine (L-dopa)-induced dyskinesia (LID) and have a more severe form than patients with old-onset Parkinson’s disease. Previous studies
Haruo Nishijima +8 more
doaj +1 more source
Cells, 2023 Dopamine replacement therapy for Parkinson’s disease is achieved using L-DOPA or dopamine D2/3 agonists, such as ropinirole. Here, we compare the effects of L-DOPA and ropinirole, alone or in combination, on patterns of glial and microvascular reactivity
Osama F. Elabi +4 more
doaj +1 more source
Striatal astrocytes act as a reservoir for L-DOPA.
PLoS ONE, 2014 L-DOPA is therapeutically efficacious in patients with Parkinson's disease (PD), although dopamine (DA) neurons are severely degenerated. Since cortical astrocytes express neutral amino acid transporter (LAT) and DA transporter (DAT), the uptake and ...
Masato Asanuma +4 more
doaj +1 more source
, 2022 The pharmacological manipulation of neuroinflammation appears to be a promising strategy to alleviate l-DOPA-induced dyskinesia (LID) in Parkinson’s disease (PD).
Patrick Pierre Michel (2019922) +5 more
core +1 more source
Neurobiology of Disease, 2011 The therapeutic benefit of L-DOPA is commonly attributed to restoration of dopamine (DA) extracellular levels in the striatum of Parkinsonian patients. However, the loss of efficacy of L-DOPA after chronic use is paradoxically associated with a similar ...
Sylvia Navailles +3 more
doaj +1 more source
Combination Treatment of Icariin and L-DOPA Against 6-OHDA-Lesioned Dopamine Neurotoxicity
Frontiers in Molecular Neuroscience, 2018 Until now, the dopamine (DA) precursor, L-3,4-dihydroxyphenylalanine (L-DOPA), remains the gold standard effective drug therapy for Parkinson’s disease (PD) patients.
Di-Sheng Lu +7 more
doaj +1 more source
Frontiers in Behavioral Neuroscience, 2014 Bradykinesia (slowness of movement) and other characteristic motor manifestations of Parkinson’s disease (PD) are alleviated by treatment with L-dihydroxyphenylalanine (L-DOPA).
Stefania eSgroi +3 more
doaj +1 more source
Evidence of
Journal of Biomedical Science, 2010 Background l-Dopa has been used for Parkinson's disease management for a long time. However, its wide variety in the rate and the extent of absorption remained challenge in designing suitable therapeutic regime.
Wang Chun-Li +5 more
doaj +1 more source
Light- or Dark-Colored, L-DOPA-Based Melanins [PDF]
, 2018 This report is a continuation of previous research on the H2O2-mediated synthesis of melanin-like pigments. We synthesized and characterized L-DOPA-based pigments using air- or H2O2-mediated oxidation.
Margaret M., Whalen +3 more
core +1 more source